What We're Reading: Page 384
Industry reads hand-picked by our editors
Dec 22, 2014
-
None
The 14 drugs most likely to top global pharma sales in 2015 and 2020
-
-
Amgen leukemia drug Blincyto's massive price tag: $178,000
-
-
GSK shingles vax shows major promise, could challenge Merck's Zostavax
-
-
Controversial pay-to-delay deals on the decline in the EU
-
-
-
Glaxo assures shareholders: Dividend payout secure despite sluggish sales
Dec 19, 2014
-
-
Actavis reveals post-merger management plans: Saunders to stay as CEO
-
-
Will this Pfizer orphan drug emerge as the Duchenne victor?
-
-
-
14 pharmacy execs arrested, 2 charged with murder over 2012 meningitis deaths
-
Report: Shire still hunting for a deal, maybe with NPS Pharma
-
-
FDA approves Novartis/Alcon's Xtoro for swimmer's ear
Dec 18, 2014
-
The 11 biggest drug launches to watch in 2015
-
-
The US Patent Office just gave a big gift to biopharma companies
-
Historic: FDA approves first-ever system to cut blood transfusion infections
-
Google Ventures ventures more aggressively into healthcare, life sciences
-
Sanofi/Regeneron's opening move on PCSK9 marketing: 'Cholesterol Counts' campaign
-
FDA forces Pfizer to put another warning on antipsychotic Geodon
-
-
-
Former Onyx CEO tackles hard-to-treat CNS diseases with new biotech
Dec 17, 2014
-
-
How Teva's CEO is preparing for a 2015 of patent expirations
-
-
The other victims of scuttled AbbVie-Shire deal? Big banks
-
-
FDA approves two new plasma-based tests, expands use of a third
-
Senate bill would give 15 years' data exclusivity to drugs for unmet needs
-
-
-
Pfizer, OPKO reach growth hormone drug pact worth up to $570M
Dec 16, 2014
-
-
Abbott closes Veropharm deal amidst US-Russia political tension
-
-
Indian Supreme Court rejects Bayer's bid to block cheap cancer generic
-
-
Jazz pushing potential $1B rare disease drug through rolling NDA
-
Federal judge: Actavis must keep selling older version of Alzheimer's drug
-
-
Novartis psoriasis drug bests J&J's Stelara in head-to-head trial
-
Dec 15, 2014
-
Philly transit authority launches class action against Gilead over Sovaldi price
-
Compromise: Branded biologics, biosimilar firms reach hard-won agreement
-
-
Teva 2015 revenue forecast $1 billion lower than expected
-
-
Gavi pledges $300M to get Ebola vaccines to hard-hit countries
-
-
-
-
Lawmakers propose new antibiotics pathway to combat superbugs
Dec 12, 2014
-
-
FDA approves new HPV super-vaccine, Merck's Gardasil 9
-
'Audition' for a job? Pfizer gets creative in its hiring approach in Sweden
-
-
Teva launches generic of Pfizer's arthritis med Celebrex in the US
-
-
Merck, NewLink Ebola vax trial suspended over joint pain complaints
-
ICYMI: AARP and GPhA on what to do about generic drug price hikes
-
-
Mylan to foot $20M tax penalty for top execs after inversion merger
Previous
